207 related articles for article (PubMed ID: 11002426)
1. TGFbeta1 represses proliferation of pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK activation.
Giehl K; Seidel B; Gierschik P; Adler G; Menke A
Oncogene; 2000 Sep; 19(39):4531-41. PubMed ID: 11002426
[TBL] [Abstract][Full Text] [Related]
2. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
3. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1.
Guha S; Lunn JA; Santiskulvong C; Rozengurt E
Cancer Res; 2003 May; 63(10):2379-87. PubMed ID: 12750255
[TBL] [Abstract][Full Text] [Related]
4. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
[TBL] [Abstract][Full Text] [Related]
5. Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta.
Ijichi H; Otsuka M; Tateishi K; Ikenoue T; Kawakami T; Kanai F; Arakawa Y; Seki N; Shimizu K; Miyazono K; Kawabe T; Omata M
Oncogene; 2004 Feb; 23(5):1043-51. PubMed ID: 14762439
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas.
Iglesias M; Frontelo P; Gamallo C; Quintanilla M
Oncogene; 2000 Aug; 19(36):4134-45. PubMed ID: 10962574
[TBL] [Abstract][Full Text] [Related]
7. TGF beta-induced focal complex formation in epithelial cells is mediated by activated ERK and JNK MAP kinases and is independent of Smad4.
Imamichi Y; Waidmann O; Hein R; Eleftheriou P; Giehl K; Menke A
Biol Chem; 2005 Mar; 386(3):225-36. PubMed ID: 15843168
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest.
Nicolás FJ; Hill CS
Oncogene; 2003 Jun; 22(24):3698-711. PubMed ID: 12802277
[TBL] [Abstract][Full Text] [Related]
10. A novel dominant negative Smad2 mutation in a TGFbeta resistant human carcinoma cell line.
Tsang KJ; Tsang D; Brown TN; Crowe DL
Anticancer Res; 2002; 22(1A):13-9. PubMed ID: 12017275
[TBL] [Abstract][Full Text] [Related]
11. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis.
Jonckheere N; Perrais M; Mariette C; Batra SK; Aubert JP; Pigny P; Van Seuningen I
Oncogene; 2004 Jul; 23(34):5729-38. PubMed ID: 15184872
[TBL] [Abstract][Full Text] [Related]
12. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses.
Suzuki K; Wilkes MC; Garamszegi N; Edens M; Leof EB
Cancer Res; 2007 Apr; 67(8):3673-82. PubMed ID: 17440079
[TBL] [Abstract][Full Text] [Related]
14. TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
Paterson IC; Davies M; Stone A; Huntley S; Smith E; Pring M; Eveson JW; Robinson CM; Parkinson EK; Prime SS
Oncogene; 2002 Feb; 21(10):1616-24. PubMed ID: 11896591
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts.
Mori Y; Ishida W; Bhattacharyya S; Li Y; Platanias LC; Varga J
Arthritis Rheum; 2004 Dec; 50(12):4008-21. PubMed ID: 15593186
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
[TBL] [Abstract][Full Text] [Related]
17. Smad2 mediates Erk1/2 activation by TGF-beta1 in suspended, but not in adherent, gastric carcinoma cells.
Lee MS; Ko SG; Kim HP; Kim YB; Lee SY; Kim SG; Jong HS; Kim TY; Lee JW; Bang YJ
Int J Oncol; 2004 May; 24(5):1229-34. PubMed ID: 15067346
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 (transforming growth factor-beta1)-mediated adhesion of gastric carcinoma cells involves a decrease in Ras/ERKs (extracellular-signal-regulated kinases) cascade activity dependent on c-Src activity.
Kim HP; Lee MS; Yu J; Park JA; Jong HS; Kim TY; Lee JW; Bang YJ
Biochem J; 2004 Apr; 379(Pt 1):141-50. PubMed ID: 14720123
[TBL] [Abstract][Full Text] [Related]
19. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
20. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]